you are here: Home News Sparc

Sparc

SPARC shares crash 19% after Psoriasis drug fails to deliver in trials
SPARC up 12% ahead of update on clinical programs, R&D pipeline this week
Sun Pharma Advanced slips 5% on halting Parkinson's drug trial
Sun Pharma inks licensing pact with SPARC to commercialise medication in US market
Trade Spotlight | What should you do with Shoppers Stop, Sharda Cropchem, SPARC, Hitachi Energy and Bajaj Auto?
SPARC inks licensing pact with Visiox Pharma for ophthalmic products
Dilip Shanghvi resigns as MD of SPARC: Here's what you need to know about him
Union Education Ministry releases Rs 80 crore to IIT Kharagpur for second phase of SPARC
'Nifty to head towards 12,700 levels, but money will likely be made in mid & smallcaps'
Abraxis Bioscience LLC dismisses patent infringement complaint against SPARC
Market Headstart: Nifty50 seen opening higher; 3 stocks which could give 5-10% return
Market Headstart | Nifty likely to open flat; 3 stocks that could give 7-12% return
Podcast | Stock picks of the day: Nifty could remain in upward consolidation mode
SPARC, Schrödinger announce research collaboration for novel CNS therapeutics
SPARC jumps 8% on successful pivotal bioequivalence study for cancer drug
Market Now: Jewellery stocks shine - PC Jeweller, Titan up 3-4%; ICICI Bank top gainer
SPARC jumps 4% on topline results of PIF and low dose PK study for dry powder inhaler
Stocks in the news: Bajaj Auto, Laurus Labs, M&M, Bhushan Steel, SPARC, Deccan Cements
SPARC spikes 7% on USFDA's complete response letter for Xelpros
Sensex, Nifty continue to fall; Midcap breaks 200-DMA, SPARC up
Buy Tata Steel, sell Infosys: Mitesh Thacker
Cadila Healthcare may test Rs 393: Rajat Bose
Buy SPARC, says Mitesh Thacker
SPARC Q4 net loss widens to Rs. 9.6 crore
Hold SPARC, says Sharmila Joshi

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Sparc

SPARC shares crash 19% after Psoriasis drug fails to deliver in trials

SPARC up 12% ahead of update on clinical programs, R&D pipeline this week

Sun Pharma Advanced slips 5% on halting Parkinson's drug trial

Sun Pharma inks licensing pact with SPARC to commercialise medication in US market

Trade Spotlight | What should you do with Shoppers Stop, Sharda Cropchem, SPARC, Hitachi Energy and Bajaj Auto?

SPARC inks licensing pact with Visiox Pharma for ophthalmic products

Dilip Shanghvi resigns as MD of SPARC: Here's what you need to know about him

Union Education Ministry releases Rs 80 crore to IIT Kharagpur for second phase of SPARC

'Nifty to head towards 12,700 levels, but money will likely be made in mid & smallcaps'

Abraxis Bioscience LLC dismisses patent infringement complaint against SPARC

Market Headstart: Nifty50 seen opening higher; 3 stocks which could give 5-10% return

Market Headstart | Nifty likely to open flat; 3 stocks that could give 7-12% return

Podcast | Stock picks of the day: Nifty could remain in upward consolidation mode

SPARC, Schrödinger announce research collaboration for novel CNS therapeutics

SPARC jumps 8% on successful pivotal bioequivalence study for cancer drug

Market Now: Jewellery stocks shine - PC Jeweller, Titan up 3-4%; ICICI Bank top gainer

SPARC jumps 4% on topline results of PIF and low dose PK study for dry powder inhaler

Stocks in the news: Bajaj Auto, Laurus Labs, M&M, Bhushan Steel, SPARC, Deccan Cements

SPARC spikes 7% on USFDA's complete response letter for Xelpros

Sensex, Nifty continue to fall; Midcap breaks 200-DMA, SPARC up

Buy Tata Steel, sell Infosys: Mitesh Thacker

Cadila Healthcare may test Rs 393: Rajat Bose

Buy SPARC, says Mitesh Thacker

SPARC Q4 net loss widens to Rs. 9.6 crore

Hold SPARC, says Sharmila Joshi